GeoVax

Atlanta, GA, United StatesFounded 2001Industry

GeoVax is a US clinical-stage vaccine company developing GEO-MVA, an investigational smallpox and mpox vaccine. Its BARDA Project NextGen award was terminated in April 2025, and the company said clinical trials of the vaccine were planned for 2025.

What it does

vaccinessmallpox/mpox vaccine candidate

Threats covered

smallpox/orthopoxviruses

Profile

GeoVax Labs is an Atlanta-area biotechnology company listed on Nasdaq (GOVX) that began in 2001 as an outgrowth of the Emory Vaccine Center, initially focused on HIV vaccines. Its CBRNE-relevant programme is GEO-MVA, an MVA-based vaccine for mpox and smallpox; the company says it is pursuing an expedited pathway with the European Medicines Agency and plans a Phase 3 immunobridging trial in late 2026.

More profile

Its BARDA Project NextGen award supported the COVID-19 vaccine candidate GEO-CM04S1, but BARDA terminated that contract for convenience in April 2025, and the company said this did not affect ongoing trials of the candidate. The company's other programmes are in cancer and infectious disease outside CBRNE.

Contract values and the date of any GEO-MVA regulatory decision were not read.

Ownership

Publicly listed on Nasdaq (GOVX)

Parent: none (publicly listed) (checked)

Sources (5)

Not verified or not found

Contract values: not read.
Whether the other programmes mentioned are active: not read.
Regulatory timeline: company statement, not independently confirmed.

Questions

What does GeoVax do?

Where is GeoVax based?

HQ (as found): Atlanta, GA. HQ country: US.

Who owns GeoVax?

Publicly listed on Nasdaq (GOVX). Parent: none (publicly listed) (checked)

Profiles are compiled from public sources and sampled-checked, not fully audited. Last verified 17 October 2026. Report a correction